An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210 Combination With BP102 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Whose PD-L1 Positive and EGFR/ALK Wild Type.
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2018
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Camrelizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 18 Sep 2018 New trial record